×
Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
https://ascopost.com/news/may-2020/is-sentinel-lymph-node-biopsy-alone-oncologically-safe-for-patients-with-early-stage-cervical-cancer/

May 29th, 2020 - In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node biopsy alone was a valid standard of care, or if bilateral pelvic lymphadenectomy—the current “gold ...

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Intensive Remote Monitoring of High-Risk Patients Initiating Antineoplastic Treatment
https://ascopost.com/news/may-2020/intensive-remote-monitoring-of-high-risk-patients-initiating-antineoplastic-treatment/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Robert Michael Daly, MD, MBA, and colleagues (Abstract 2027), use of a pilot program of intensive remote monitoring of high-risk outpatients receiving antineoplastic treatment has shown considerable promise in the ability to improve patient care and decrease use of hospital resources by promptly alerting practitioners to symptoms that requ...

Precision Medicine on a Large Scale for Pediatric Patients With Cancer
https://ascopost.com/news/may-2020/precision-medicine-on-a-large-scale-for-pediatric-patients-with-cancer/

May 28th, 2020 - Although 84% of children with cancer survive 5 years or more, children with refractory, relapsed, and progressive high-risk malignancies have a poor median survival of 9.5 months. The German INFORM registry is a large prospective, noninterventional, multicenter study collecting clinical and molecular data on pediatric patients with refractory, relapsed, and progressive malignant cancers. The st...

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
https://ascopost.com/news/may-2020/patients-with-cancer-especially-progressive-disease-infected-with-covid-19-may-have-an-increased-risk-of-death/

May 28th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 28th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Adjuvant Osimertinib ‘Exceeds Expectations’ in Early-Stage EGFR-Positive NSCLC
https://ascopost.com/news/may-2020/adjuvant-osimertinib-exceeds-expectations-in-egfr-positive-nsclc/

May 27th, 2020 - Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim analysis of the phase III ADAURA trial were reported at the ASCO20 Virtual Scientific Program and f...

Addressing rural disparities in cancer care via telehealth.
https://meetinglibrary.asco.org/record/190608
Laurence J. Heifetz, MD

May 28th, 2020 - Background: Patients in rural areas have reduced access to high-quality cancer care, which contributes to rural-urban disparities in cancer mortality. Telehealth technologies can connect providers across rural and urban communities. Methods: In 2006, one author (LH) established an oncology program in Truckee, CA, a rural community with a single critical access hospital without oncology services...

Colorectal cancer: Improving screening in rural clinic.
https://meetinglibrary.asco.org/record/190695
Thuy Thanh Thi Le, DO

May 28th, 2020 - Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. From 2010 to 2014, CRC was also the second leading cause of cancer deaths in North Carolina (NC). Between 2012-2016, the age adjusted mortality rate was 18-25 per 100,000 persons in Robeson County, NC. During this timeframe, it is estimated that if all people aged 50 and older in NC we...

Using implementation science to examine impact of a social responsibility agenda on addressing cancer health disparities in ceará, Brazil.
https://meetinglibrary.asco.org/record/190521
Hermano Alexandre Lima Rocha, MD, MPH, PhD

May 28th, 2020 - Background: Programs to address disparities in cancer care outcomes in resource-limited settings require attention to social determinants of health (SDoH) to achieve successful clinical care implementation. The Instituto de Câncer do Ceará, the largest cancer center in northeastern Brazil, has implemented a Social Responsibility Agenda (SRA) to guide equitable cancer care delivery. This goal of...

Physician perceptions about goals of care of hospitalized patients with malignancies.
https://meetinglibrary.asco.org/record/190604
Nino Balanchivadze, MD

May 28th, 2020 - Background: More sophisticated treatment techniques in cancer management have led to increased complexity in patient care. The perception of cancer outcomes is different between physicians and may result in premature hospice referral in hospitalized patients with or without cancer-related acute illness. We created a clinical scenario-based survey to assess perceptions of goals of care choices o...

Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma (CSCC): A cost-effectiveness analysis.
https://meetinglibrary.asco.org/record/190622
Eleanor Paul

May 28th, 2020 - Background: Cemiplimab is a high-affinity, human, hinge-stabilized, monoclonal antibody that potently blocks the interactions of programmed cell death-1 (PD-1) with programmed cell death ligand-1 (PD-L1) and PD-L2. In September 2018, cemiplimab-rwlc became the first systemic therapy approved by the US Food and Drug Administration for the treatment of patients with advanced CSCC ineligible for c...

Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
https://meetinglibrary.asco.org/record/189151
Monica Motwani, PhD

May 28th, 2020 - Background: Eftozanermin alfa (eftoza; formerly known as ABBV-621), a 2nd-generation tumor necrosis factor-related apoptosis-inducing ligand receptor agonist, is being evaluated in previously treated solid and hematologic malignancies (NCT03082209). In a dose-expansion cohort, patients (pts) with KRAS-mutant colorectal cancer (n = 24) and pancreatic cancer (n = 24) were evaluated at 3 dose leve...

Perspectives on healthcare providers’ role in health promotion among cancer survivors.
https://meetinglibrary.asco.org/record/189980
Karina I. Halilova, MD, MPH

May 28th, 2020 - Background: To further integrate health promotion into cancer survivorship care, we explored multilevel perspectives on potential roles healthcare providers could have in promoting uptake of web-based healthy lifestyle programs among cancer survivors. Methods: In developing the Aim, Plan, and Act on Lifestyles (AMPLIFY) Survivor Health diet and exercise web-based program, we conducted 10 focus ...

Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity.
https://meetinglibrary.asco.org/record/188978
Philip Tatman

May 28th, 2020 - Background: Large public cancer databases have allowed identification of novel mechanisms of oncogenesis and development of pharmacotherapies targeting these pathways. Examples are the androgen receptor (AR) and glucocorticoid receptor (GR). The Cancer Genome Atlas (TCGA) shows these receptors to have significantly increased expression over matched, normal tissue in several cancer types includi...

Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.
https://meetinglibrary.asco.org/record/189973
Terry L. Ng, MD

May 28th, 2020 - Background: Randomized clinical trials evaluated bone modifying agents (BMAs) such as bisphosphonates and denosumab for bone metastases for 1-2 years in duration even though BMA therapy is commonly administered for much longer. A systematic review on the risk-benefit of continuing BMAs for longer than 2 years in breast cancer or castrate-resistant prostate cancer was conducted. Methods: Medline...

Development and validation of a novel EHR-based tumor progression outcome to support biomarker discovery.
https://meetinglibrary.asco.org/record/190482
Kenneth L. Kehl, MD, MPH

May 28th, 2020 - Background: Obtaining clinical outcomes for analysis has historically been a critical barrier to cancer genomics research. EHRs could constitute an important data source to bridge this gap, but EHRs rarely capture structured outcomes such as cancer progression. Novel, robust methods are needed to capture clinically relevant outcomes from EHRs. Methods: Among patients with lung adenocarcinoma wh...

Retrospective chart review to characterize admission to the ICU in the last 30 days of life and use of systemic anticancer therapy in the last two weeks of life at the Lifespan Cancer Institute.
https://meetinglibrary.asco.org/record/190626
Han You, MD

May 28th, 2020 - Background: Admission to the ICU in the last 30 days of life and use of systemic anticancer therapy in the last 2 weeks of life are indicators of overly aggressive end-of-life care and have been incorporated into the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as benchmarks to assess care across cancer centers. We sought to better define the proporti...

Dual TGF-β and AURKA targeting enhances chemosensitivity in triple-negative breast cancer.
https://meetinglibrary.asco.org/record/188656
Fahad Ahmed Faruqi, MD, MPH

May 28th, 2020 - Background: Chemotherapy resistance remains a significant barrier in the effective treatment of patients with triple negative breast cancer (TNBC). TGF-β signaling is a well characterized oncogenic pathway in TNBC that promotes chemoresistance by inducing epithelial to mesenchymal transition (EMT) and tumor stemness. Aurora-A kinase (AURKA) is a serine/threonine kinase responsible for chromosom...